HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Lowers Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein maintains a Buy rating on Denali Therapeutics (NASDAQ:DNLI) but lowers the price target from $105 to $95.

February 28, 2024 | 5:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Denali Therapeutics' price target was reduced from $105 to $95 by HC Wainwright & Co., although the Buy rating was maintained.
The reduction in price target might initially concern investors, potentially putting short-term pressure on DNLI's stock price. However, the maintenance of a Buy rating by a reputable analyst firm like HC Wainwright & Co. suggests underlying confidence in the company's long-term prospects. This mixed signal could lead to neutral short-term price movement as the market digests both the lowered price target and the continued endorsement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100